October 02, 2014

Bayer launches jumbo bond issuance with a volume of USD 7 billion

Successful placement as part of the financing of the acquisition of the OTC business of Merck & Co., Inc., United States / Six tranches with maturities of two to ten years
Leverkusen, October 2, 2014 - The Bayer Group is issuing a jumbo bond in
144A/Reg S format with a volume of USD 7 billion through its subsidiary Bayer
U.S. Finance LLC, Pittsburgh, United States. The bond comprises six tranches
with short-, mid- and long-term maturities. The U.S.dollar bond makes up part
of the financing of the acquisition of the OTC business of Merck & Co., Inc.,
United States.

The short-term paper is a two-year variable tranche with a volume of USD 0.5
billion and a coupon of 0.25 percent above the three-month USD Libor rate.

The mid-term bond with a volume of USD 1.25 billion and a maturity of three
years has a USD 850 million fixed rate portion (1.5 percent coupon) and a USD
400 million part with variable rate (coupon 0.28 percent above the three-month
USD Libor rate).

A five-year bond with a volume of USD 2 billion was priced with a coupon of
2.375 percent.

The long-term tranches with a volume of USD 1.5 billion maturing in 2021 and
USD 1.75 billion maturing in 2024 will pay a coupon of 3.0 percent (seven
years) and 3.375 percent (ten years).

The net cash provided by the U.S. bond will replace part of the bridge
financing already secured by Bayer in May 2014 in connection with the takeover
agreement with Merck & Co., Inc., United States. A further component of the
financing is a USD 2 billion loan with a term of four years, which was provided
by the same consortium of 26 banks as the bridge financing. In June, the
company had already issued a two-tranche hybrid bond with a total volume of EUR
3.25 billion.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the fields of health
care, agriculture and high-tech polymer materials. As an innovation company, it
sets trends in research-intensive areas. Bayer's products and services are
designed to benefit people and improve their quality of life. At the same time,
the Group aims to create value through innovation, growth and high earning
power. Bayer is committed to the principles of sustainable development and to
its social and ethical responsibilities as a corporate citizen. In fiscal 2013,
the Group employed 113,200 people and had sales of EUR 40.2 billion. Capital
expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 3.2 billion. For
more information, go to www.bayer.com.


Forward-looking statements

This news release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports, which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or
developments.

United States
This news release does not constitute an offer to sell securities, or a
solicitation of an offer to buy securities, in the United States of America.
Securities may not be offered or sold in the United States of America absent
registration or an exemption from registration under the U.S. Securities Act of
1933, as amended (the "Securities Act"). The securities of the Bayer Group
described herein have not been and will not be registered under the Securities
Act, or the laws of any State, and may not be offered or sold within the United
States, except pursuant to an exemption from, or in a transaction not subject
to, the registration requirements of the Securities Act and applicable State
laws. Bayer does not intend to register any portion of the offering in the
United States or conduct a public offering of securities in the United States.